GRAL · GRAIL, Inc.
$77.97
+4.01 (+5.42%)
At close · Aug 20
Market Cap
$3.30B
Shares
44.67M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$77.97
Open$73.77
Day$73.77–81.85
52W close$31.61–116.06
Avg vol 30d665K
Short int7.5M · 16.8% float · 15.3d
Short vol75%
Last earningsAug 5, 2026
DataJun 2024–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 3, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+6%
above
Price vs 50-day avg
+14%
above
RSI (14)
60
neutral
MACD trend
Positive
52-week position
55%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+11%
trailing
6-month return
+46%
trailing
YTD return
−9%
this year
Relative strength
+35%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $68 › 200d $73 — 200d above 50d
Institutional flow
Accumulating
+1% holders QoQ · +65 funds added
Insider flow
Distributing
Net -$91.1K over 90 days · 100% sells
Short interest
Falling
16.77% of float · ▼ -3.1% MoM · 15.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
376 holders — mid 2-yr range
Squeeze score
74
high risk · 0–100
Fundamentals
Revenue growth
+17%
Y/Y
EPS growth
+83%
Y/Y
Free cash flow
$-299.9M
Balance sheet
$249.7M
net cash
Quant / Vol
risk profile
Volatility
101%
annualized · 1-yr
Max drawdown
−63%
past year
ATR
6.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jan 12, 2026
Cash burn
· 2026
up to $300M
Prior guidance
period ended
· from the Earnings Call filed Sep 30, 2025
Cash burn
· full year 2025
up to $290M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+6%
Bullish
Price vs 50-day avg
+14%
Bullish
RSI (14)
60
Neutral
MACD trend
Positive
Bullish
52-week position
55%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $68 › 200d $73 — 200d above 50d
Institutional flow
Accumulating
+1% holders QoQ · +65 funds added
Insider flow
Distributing
Net -$91.1K over 90 days · 100% sells
Short interest
Falling
16.77% of float · ▼ -3.1% MoM · 15.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
376 holders — mid 2-yr range
Price context
position in its 52-week range
Range low $32
Now $78 · 55%
Range high $116
vs 200-day avg +6%
vs 50-day avg +14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -170.19M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted Gross Profit non-GAAP | 41.25M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Cash position | $823.1M | Q1 2026 | — |
| Galleri Tests Sold | 185,000 | full year 2025 | — |
| >800k In market with Galleri MCED test | 800K | as of January 12, 2026 | — |
| Cash burn | $274M | FY2025 | — |
| Commercial Galleri® tests sold to-date | 475K | as of January 12, 2026 | — |
| Prescriber growth over 2024 | 30% | as of December 31, 2025 | — |
| Test capacity at RTP site | 1M | as of January 12, 2026 | — |
| Total Galleri volume growth over 2024 | 35% | FY2025 | — |
| Unique prescribers since launch | 17K | as of December 31, 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GRAL
this stock
GRAIL, Inc.
|
$3.30B | -8.9% | +17.2% | — | 16.8% |
|
TMO
Thermo Fisher Scientific Inc.
|
$231.21B | +8.3% | +14.5% | 33.6 | 1.3% |
|
DHR
Danaher Corp /De/
|
$147.41B | -5.7% | +8.5% | 37.2 | 1.7% |
|
NTRA
Natera, Inc.
|
$46.86B | +41.8% | -2.8% | — | 3.0% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.29B | -19.3% | +10.4% | 39.5 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GRAL | +14.3% | +10.8% | +46.5% | +13.7% | -8.9% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +16.2% | +7.5% | +35.3% | +11.7% | -20.7% |
Key facts
CIK
1699031
CUSIP
384747101
13F (30d)
352 filings
338 filers
Visit website
Investor relations